Figure 2. 1: Drug efflux phenomenon in multidrug resistant cells 8

Figure 2. 2: Structure of P-glycoproteins 9

Figure 2. 3: Nanoparticle bound drug is retained in the cytoplasm 18

Figure 2. 4: Schematic illustration of the EPR effect principle. Angiogenesis and enhanced vascular permeability of tumour capillaries and impaired or missing lymphatic clearance of macromolecules result in accumulation of macromolecules (polymers) in tumour tissue. 22

Figure 3. 1: FTIR spectra of paclitaxel 33

Figure 3. 2: Regressed calibration curve of PTX in $CHCl_3$: MeOH 35

Figure 3. 3: Regressed calibration curve of PTX in ACN 35

Figure 3. 4: Regressed calibration curve of PTX in pH 7.4 PBS containing 20% Ethanol 36

Figure 3. 5: 1st derivative regressed calibration curve of PTX in ACN 38

Figure 3. 6: Regressed calibration curve of PTX in ACN: water 39

Figure 3. 7: Regressed calibration curve of PTX in rat plasma 41

Figure 3. 8: Overlay chromatogram of blank plasma and plasma spiked with PTX 42

Figure 3. 9: Overlay chromatogram of blank liver homogenate and liver homogenate spiked with PTX 44

Figure 3. 10: Overlay chromatogram of blank spleen homogenate and spleen homogenate spiked with PTX 44

Figure 3. 11: Overlay chromatogram of blank kidney homogenate and kidney homogenate spiked with PTX 45

Figure 3. 12: Overlay chromatogram of blank lung homogenate and lung homogenate spiked with PTX 45

Figure 3. 13: Overlay chromatogram of blank heart homogenate and heart homogenate spiked with PTX 46

Figure 3. 14: Overlay chromatogram of blank tumor homogenate and tumor homogenate spiked with PTX 46

Figure 3. 15: Regressed calibration curve of coumarin-6 in ACN 48

Figure 3. 16: Emission peaks of coumarin-6 49

Figure 3. 17: Regressed calibration curve of coumarin-6 in ACN 50

Figure 3. 18: Regressed calibration curve for determination of residual PVA 52

Figure 3. 19: Regressed calibration curve of Tf by BCA method 53

Figure 4. 1: Schematic presentation of formation of nanoparticles by nanoprecipitation technique 60

Figure 4. 2: Contour plots of effect of PLGA concentration and Organic to aqueous phase volume ratio on PS (a) -1 level of X_2 (b) 0 level of X_2 (c) +1 level of X_2 67

Figure 4. 3: Contour plot of effect of PVA concentration and Organic to aqueous phase volume ratio on EE(a) -1 level of X_2 (b) 0 level of X_2 (c) +1 level of X_2 69

Figure 4. 4: Contour plots of effect of concentration of lecithin and poloxamer on PS (a) -1 level of X_2 (b) 0 level of X_2 (c) +1 level of X_2 84

Figure 4. 5: Contour plots of effect of concentration of lecithin and poloxamer on PS (a) -1 level of X_2 (b) 0 level of X_2 (c) +1 level of X_2 86

Figure 4. 6: NMR spectra of Tf conjugated to PLGA NPs 98

Figure 4. 7: Schematic diagram of conjugation of Tf on PLGA NP surface 98

Figure 4. 8: In-vitro release of PTX in pH 7.4 PBS containing 20% ethanol 104

Figure 4. 9: DSC thermograms 105

Figure 4. 10: TEM images of PLGA NPs (a) unconjugated (b) Tf- conjugated 106

Figure 4. 11: (A) Alkyl cyanoacrylate molecule (B) Anionic polymerization process of alkyl cyanoacryaltes. 108

Figure 4. 12: Effect of monomer concentration on PS and EE of PBCA NPs prepared by EPand DP technique 110

Figure 4. 13: Effect of surfactant concentration on PS and EE of PBCA NPs prepared by EPand DP technique 110

Figure 4. 14: Effect of surfactant type on PS and EE of PBCA NPs prepared by EPand DP technique 114

Figure 4. 15: Effect of temperature on PS and EE of PBCA NPs prepared by EPand DP technique 115

Figure 4. 16: Effect of PTX concentration on PS and EE of PBCA NPs prepared by EPand DP technique 119

Figure 4. 17: Effect of pH on PS and EE of PBCA NPs 119

Figure 4. 18: Turbidimetric measurement for particle formation by EP and DP technique 120

Figure 4. 19: In-vitro release of PTX in pH 7.4 PBS containing 20% ethanol 123

Figure 4. 20: FTIR spectra of (a) BCA monomer and (b) PBCA NPs 124

Figure 4. 21: DSC thermograms of (a) PTX (b) PBCA NPs and (c) PTX loaded PBCA NPs 125

Figure 4. 22: GPC chromatogram 126

Figure 4. 23: NMR spectra of PBCA 127

Figure 4. 24: TEM image of PBCA NPs (a) NPs prepared by DP technique and (b) NPs prepared by EP technique 128

Figure 4. 25: In-vitro release of PTX in pH 7.4 PBS containing 20% ethanol 135

Figure 4. 26: DSC thermograms (a) PTX (b) GTS and (c) PTX GTS SLN 136

Figure 4. 27: X-ray diffraction pattern of (a) PTX, (b) GTS and (c) PTX GTS SLN 138

Figure 4. 28: TEM image of PTX GTS SLN 138

Figure 4. 29: Steric stability test of PTX loaded GTS SLN prepared with 1% poloxamer 188 concentration 139

Figure 4. 30: In-vitro release of PTX after storage for 6 months at 5°C ± 3°C 145

Figure 4. 31: In-vitro release of PTX after storage for 6 months at 5°C ± 3°C.....145
Figure 4. 32: In-vitro release of PTX after storage for 3 months at 25 ± 2°C/60 ± 5% RH.....146
Figure 4. 33: In-vitro release of PTX after storage for 3 months at 25 ± 2°C/60 ± 5% RH.....146
Figure 5. 1: Fluorescent images of intracellular uptake of coumarin-6 loaded nanoparticle formulations after 4hrs incubation 161
Figure 5. 2: Uptake efficiency of coumarin-6 loaded PLGA NPs.....163
Figure 5. 3: Uptake efficiency of coumarin-6 loaded Pluronic®P85 coated PLGA NPs 163
Figure 5. 4: Uptake efficiency of coumarin-6 loaded Tf PLGA NPs.....164
Figure 5. 5: Uptake efficiency of coumarin-6 loaded Tf PLGA NPs in presence of free Tf 164
Figure 5. 6: Uptake efficiency of coumarin-6 loaded PBCA NPs.....165
Figure 5. 7: Uptake efficiency of coumarin-6 loaded GTS SLN 165
Figure 5. 8: Cell viability at 24h 170
Figure 5. 9: Cell viability at 48h 171
Figure 5. 10: Cell viability at 72h 172
Figure 6. 1: (A) Normal rat (B) Rat with a subcutaneous C6 glioma.....177
Figure 6. 2: Plasma PTX concentration Vs time profiles for PTX solution and NPs 181
Figure 6. 3: Liver PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....184
Figure 6. 4: Spleen PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....184
Figure 6. 5: Lung PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....185
Figure 6. 6: Kidney PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....185
Figure 6. 7: Heart PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....186
Figure 6. 8: Tumor PTX concentrations after i.v. administration in rats at dose of 20mg/kg.....186